| Today’s Big NewsAug 8, 2023 |
| By Angus Liu After overseeing the approval of KRAS inhibitor Krazati, Mirati Therapeutics CEO David Meek is stepping down. The change comes as Mirati prepares to start a pivotal trial for Krazati and Keytruda in PD-L1-high lung cancer patients. |
|
|
|
By Fraiser Kansteiner Emergent is de-emphasizing its focus on its CDMO services business. As part of the move, Emergent will scale back operations at its Bayview facility in Baltimore, Maryland, as well as its plants in Canton, Massachusetts, and Rockville, Maryland. |
By Annalee Armstrong Pfizer’s decision to drop an obesity candidate on liver toxicity concerns in June raised a red flag for the analyst community. Could Eli Lilly’s prize-winning obesity portfolio have similar issues? |
By Andrea Park Neuralink, the Elon Musk-founded company developing an implant he’s described as “a Fitbit in your skull,” recently announced that it had gotten the go-ahead from the FDA to begin clinical trials—and now, it has secured extra funding to see the studies through. |
|
Thursday, August 3, 2023 | 11am ET / 8am PT Join us for this insightful discussion on how to unlock the full potential of liquid biopsy and be an integral part of the future of precision medicine. We’ll take a deep dive into the latest strategies and solutions designed to help overcome current challenges and empower researchers and clinicians with enhanced capabilities. Register now.
|
|
By Fraiser Kansteiner In a large phase 3 trial, Wegovy cut the risk of major adverse cardiovascular events by 20% compared with placebo and standard of care, Novo said Tuesday. Specifically, investigators measured Wegovy's 2.4-mg dose for its ability to cut the risk of a cardio death, heart attack or stroke. |
By Conor Hale Hand-held ultrasound developer Butterfly Network is clipping its wings with a plan to extend its cash runway, in part by reducing operating costs by an average of $2 million per month. |
By Zoey Becker Eli Lilly expects supply strains for popular diabetes med Mounjaro to let up next year. And the Indianapolis pharma isn't deterred by new trial results from rival Novo Nordisk's Wegovy, which could boast a cardiovascular edge. |
By James Waldron Bayer has dropped an acute respiratory distress syndrome drug in phase 2 development for “scientific reasons,” the German pharma giant revealed in its latest earnings results. |
By Andrea Park A group of researchers from the University of New South Wales in Sydney has stepped up to develop an app that aims to retrain and improve the action of walking in people with Parkinson’s disease. |
By Gabrielle Masson Kiora Pharmaceuticals is narrowing its line of sight to only two assets that tackle rare retinal diseases, while two other programs will be handed off to prospective partners. |
By Kevin Dunleavy In his first quarterly earnings call since taking over as CEO at Bayer, Bill Anderson faced several questions about the structure of the company. He said to stay tuned until early 2024. The company reported a 14% decline in revenue for the quarter, with all three business sectors seeing a drop in sales. |
By Nick Paul Taylor Nektar Therapeutics has accused Eli Lilly of botching the analysis of data from phase 1b trials in eczema and psoriasis. Lilly, which has reportedly confirmed the errors, handed back rights to rezpeg earlier this year. |
Fierce podcastsDon’t miss an episode |
| This week on "The Top Line," we discuss how to support patients during the cancer drug shortage, plus this week's headlines. |
|
|---|
|
|
|
Wednesday, August 30, 2023 | 1pm ET/ 10am PT Enzymes have long demonstrated their utility as a green alternative to metal-based catalysts, but the evolution time required can be significant. Join this webinar to learn about an extracellular strategy that reduces the evolution cycle and enables biocatalysis to be used much earlier in development. Register now.
|
|
| WhitepaperLeading facilities practices and technologies can help improve the productivity of your research and manufacturing operations—and accelerate the journey from laboratory to saving lives. Sponsored by: JLL |
| WhitepaperIn oncology, traditional methods for determining sales force size & structure are no longer appropriate. This paper describes the multiple drivers of sales strategy in oncology markets today. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| ResearchLearn how the right chemical inventory strategy helped save a mid-size CDMO millions of dollars while securing a stable supply of products with just-in-time delivery. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
| WebinarDownload this webinar to learn how to avoid pitfalls when characterizing CAR-T cells in your development workflow, how to save time by using one antibody to examine your entire panel of CARs, and more. Sponsored by: Cell Signaling Technology |
| WhitepaperLearn more about the current challenges and issues that eClinical technology providers are facing. Sponsored by: YPrime |
| |
|
